Synthesis, biological activities, and molecular docking studies of triazolo[4,3-b]triazine derivatives as a novel class of α-glucosidase and α-amylase inhibitors
© 2024 Deutsche Pharmazeutische Gesellschaft..
In diabetes mellitus, amylase and glucosidase enzymes are the primary triggers. The main function of these enzymes is to break macromolecules into simple sugar units, which directly affect blood sugar levels by increasing blood permeability. To overcome this metabolic effect, there is a need for a potent and effective inhibitor capable of suppressing the enzymatic conversion of sugar macromolecules into their smaller units. Herein, we reported the discovery of a series of substituted triazolo[4,3-b][1,2,4]triazine derivatives as α-glucosidase and α-amylase inhibitors. All target compounds demonstrated significant inhibitory activities against α-glucosidase and α-amylase enzymes compared with acarbose as the positive control. The most potent compound 10k, 2-[(6-phenyl-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)thio]-N-[4-(trifluoromethyl)phenyl]acetamide, demonstrated IC50 values of 31.87 and 24.64 nM against α-glucosidase and α-amylase enzymes, respectively. To study their mechanism of action, kinetic studies were also done, which determined the mode of inhibition of both enzymes. Molecular docking was used to confirm the binding interactions of the most active compounds.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Archiv der Pharmazie - (2024) vom: 19. März, Seite e2300628 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Seyfi, Soheila [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
α-amylase |
|---|
| Anmerkungen: |
Date Revised 19.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1002/ardp.202300628 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369915151 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369915151 | ||
| 003 | DE-627 | ||
| 005 | 20240319233751.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240319s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ardp.202300628 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1336.xml |
| 035 | |a (DE-627)NLM369915151 | ||
| 035 | |a (NLM)38501879 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Seyfi, Soheila |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synthesis, biological activities, and molecular docking studies of triazolo[4,3-b]triazine derivatives as a novel class of α-glucosidase and α-amylase inhibitors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 Deutsche Pharmazeutische Gesellschaft. | ||
| 520 | |a In diabetes mellitus, amylase and glucosidase enzymes are the primary triggers. The main function of these enzymes is to break macromolecules into simple sugar units, which directly affect blood sugar levels by increasing blood permeability. To overcome this metabolic effect, there is a need for a potent and effective inhibitor capable of suppressing the enzymatic conversion of sugar macromolecules into their smaller units. Herein, we reported the discovery of a series of substituted triazolo[4,3-b][1,2,4]triazine derivatives as α-glucosidase and α-amylase inhibitors. All target compounds demonstrated significant inhibitory activities against α-glucosidase and α-amylase enzymes compared with acarbose as the positive control. The most potent compound 10k, 2-[(6-phenyl-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)thio]-N-[4-(trifluoromethyl)phenyl]acetamide, demonstrated IC50 values of 31.87 and 24.64 nM against α-glucosidase and α-amylase enzymes, respectively. To study their mechanism of action, kinetic studies were also done, which determined the mode of inhibition of both enzymes. Molecular docking was used to confirm the binding interactions of the most active compounds | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a molecular docking | |
| 650 | 4 | |a α-amylase | |
| 650 | 4 | |a α-glucosidase | |
| 700 | 1 | |a Salarinejad, Somayeh |e verfasserin |4 aut | |
| 700 | 1 | |a Moghimi, Setareh |e verfasserin |4 aut | |
| 700 | 1 | |a Toolabi, Mahsa |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghian, Nastaran |e verfasserin |4 aut | |
| 700 | 1 | |a Tüzün, Burak |e verfasserin |4 aut | |
| 700 | 1 | |a Firoozpour, Loghman |e verfasserin |4 aut | |
| 700 | 1 | |a Ketabforoosh, Shima H M E |e verfasserin |4 aut | |
| 700 | 1 | |a Taslimi, Parham |e verfasserin |4 aut | |
| 700 | 1 | |a Foroumadi, Alireza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archiv der Pharmazie |d 1972 |g (2024) vom: 19. März, Seite e2300628 |w (DE-627)NLM000013323 |x 1521-4184 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:19 |g month:03 |g pages:e2300628 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ardp.202300628 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 19 |c 03 |h e2300628 | ||